Arquivamento definitivo - Art. 33 da LPI
#11.1.1
12/24/2024
RPI 2816
Application data
Number
112023005196Type
Filing
Publication
PCT
US2021071609 The application was abandoned: examination was not requested within the 36 months following the 09/27/2021 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.
Talk to a specialistLatest action published by the INPI: 12/24/2024. We update with every new RPI gazette, published weekly.
Applicants
SEAGEN INC.
US
Inventors
H. L. (pessoa física)
US
M. O. (pessoa física)
US
Z. W. (pessoa física)
US
IPC Classification
Priority claims
US
63/084,444 · 09/28/2020
US
63/243,025 · 09/10/2021
Abstract
ANTICORPOS ANTI-LIV1 HUMANIZADOS PARA O TRATAMENTO DE CÂNCER.São providos métodos para usar anticorpos anti-LIV1 e conjugados anticorpo-fármaco, incluindo conjugados anticorpo-fármaco anti-LIV1, para inibir a proliferação de uma célula, bem como para o tratamento de cânceres, tais como, por exemplo, câncer de próstata e melanoma.
Publications in the Brazilian Industrial Property Gazette (RPI).
#11.1.1
12/24/2024
RPI 2816
#11.1
10/08/2024
RPI 2805
#1.3
05/30/2023
RPI 2734
#1.1
03/28/2023
RPI 2725
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.